Validation of the MiCK Assay

Pierian Biosciences21 enrolled

Overview

Testing Mayo Clinic cancer patients with the results being correlated with prior patient therapy, performance status, and extent of disease.

This study will be conducted in two phases. During the Feasibility Phase, specimens from any tumor will be sent to the central DiaTech MiCK assay laboratory to determine the ease of sample acquisition, processing, transport, and assay interpretation. Once DiaTech has completed analyses for the feasibility phase specimens and has confirmed that the sample acquisition, processing, transport, and assay interpretation are appropriate, we will proceed with the Demonstration Phase. During the Mesothelioma Demonstration Phase, 20 mesothelioma samples will be assayed and the results will be correlated with prior patient therapy, performance status, and extent of disease.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Mesothelioma, Small Cell Lung Cancer, NSCLC

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 20 subjects diagnosed with mesothelioma and 10 diagnosed with any malignancy. Exclusion Criteria: * patients that a sample cannot obtained for testing.

Locations (1)

Mayo Validation Support Services 3050 Superior Drive NW

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Complete response and survival

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.